|
FR104F
(enExample)
|
1960-11-05 |
|
|
|
|
US3117160A
(en)
|
1961-07-27 |
1964-01-07 |
Pfizer & Co C |
Aralkylamines
|
|
US3198834A
(en)
|
1964-07-27 |
1965-08-03 |
Snc Science Union Et Compagnie |
Optical isomers of trifluoromethylated phenethylamines
|
|
GB1254332A
(en)
|
1969-02-27 |
1971-11-17 |
Science Union & Cie |
Amino acids and their derivatives and processes for preparing them
|
|
DE2143204C3
(de)
|
1971-08-28 |
1979-09-27 |
Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt |
N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
|
|
DE2150399A1
(de)
|
1971-10-09 |
1973-04-12 |
Hoechst Ag |
Neue oxime
|
|
GB1413078A
(en)
|
1973-07-27 |
1975-11-05 |
Beecham Group Ltd |
Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
|
|
GB1413070A
(en)
|
1973-07-27 |
1975-11-05 |
Beecham Group Ltd |
Process for the production of - norfenfluramine and - fenfluramine and salts thereof
|
|
US4452815A
(en)
|
1980-06-16 |
1984-06-05 |
Massachusetts Institute Of Technology |
Method of utilizing d,l-fenfluramine for modifying feeding behavior
|
|
US4309445A
(en)
|
1980-06-16 |
1982-01-05 |
Massachusetts Institute Of Technology |
d-Fenfluramine for modifying feeding behavior
|
|
DE3717434C1
(de)
|
1987-05-23 |
1988-09-15 |
Degussa |
Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
|
|
US4857553A
(en)
|
1987-08-06 |
1989-08-15 |
A. H. Robins Company, Incorporated |
Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
|
|
KR890003368A
(ko)
|
1987-08-06 |
1989-04-14 |
원본미기재 |
특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
|
|
HU204497B
(en)
|
1989-10-09 |
1992-01-28 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing phenfluramine
|
|
IT1238686B
(it)
|
1990-02-09 |
1993-09-01 |
Lab Mag Spa |
Procedimento per la preparazione di levo e destro fenfluramina
|
|
FR2684552B1
(fr)
|
1991-12-06 |
1995-04-28 |
Adir |
Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
|
|
US5985880A
(en)
|
1996-06-05 |
1999-11-16 |
Delta Pharmaceuticals |
Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
|
|
JP3342491B2
(ja)
|
1993-08-06 |
2002-11-11 |
ファルマシア・アンド・アップジョン・カンパニー |
選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
|
|
US5834477A
(en)
|
1993-12-08 |
1998-11-10 |
The United States Of America As Represented By The Secretary Of The Army |
Opiate analgesic formulation with improved safety
|
|
US5412102A
(en)
|
1994-05-27 |
1995-05-02 |
Syntex (U.S.A.) Inc. |
Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
|
|
ES2157330T3
(es)
|
1994-06-03 |
2001-08-16 |
Thejmde Trust |
Composicion que comprende aril-alquil-amina meta substituida, usos terapeuticos y diagnosticos.
|
|
IT1298349B1
(it)
|
1996-05-29 |
2000-01-05 |
Alfa Chem Ital |
Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
|
|
IT1292885B1
(it)
|
1997-04-28 |
1999-02-11 |
Alfa Chem Ital |
Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
|
|
EP0920864A1
(en)
|
1997-12-03 |
1999-06-09 |
Pfizer Products Inc. |
Combination therapy including a specific beta-3 agonist and an anorectic agent
|
|
US20020098175A1
(en)
|
1998-06-16 |
2002-07-25 |
Zohoungbogbo Mathias C. |
Dietetic food composition and dietetic method using such composition
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
CA2355293C
(en)
|
1998-12-23 |
2005-08-16 |
Orphan Medical, Inc. |
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
|
|
US20080103179A1
(en)
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
|
US7124031B1
(en)
|
2000-05-11 |
2006-10-17 |
Medco Health Solutions, Inc. |
System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
|
|
AU2001275095A1
(en)
|
2000-07-17 |
2002-01-30 |
Opt-E-Scrip, Inc. |
Single-patient drug trials used with accumulated database
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
US7585493B2
(en)
|
2001-05-24 |
2009-09-08 |
Alexza Pharmaceuticals, Inc. |
Thin-film drug delivery article and method of use
|
|
US6737042B2
(en)
|
2001-05-24 |
2004-05-18 |
Alexza Molecular Delivery Corporation |
Delivery of drug esters through an inhalation route
|
|
ES2339339T3
(es)
|
2001-06-22 |
2010-05-19 |
Universite Catholique De Louvain |
Perlas o capsulas de hidrogel como medios artificiales para la oviposicion de insectos y la cria de endoparasitoides.
|
|
NZ530889A
(en)
|
2001-07-31 |
2005-03-24 |
Wyeth Corp |
Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
|
|
AUPR732601A0
(en)
|
2001-08-28 |
2001-09-20 |
Polychip Pharmaceuticals Pty Ltd |
Methods for the synthesis of amines such as ephedrine and inter mediates
|
|
CN100350968C
(zh)
|
2001-09-24 |
2007-11-28 |
皇家创新有限公司 |
饮食行为的改进
|
|
RU2317104C2
(ru)
|
2001-09-24 |
2008-02-20 |
Импиэриэл Инноувейшнс Лимитид |
Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
|
|
US6599901B1
(en)
|
2001-11-19 |
2003-07-29 |
Hoffman-La Roche Inc. |
Pyridone substituted benzothiazole derivatives
|
|
US7101572B2
(en)
*
|
2001-12-07 |
2006-09-05 |
Unilab Pharmatech, Ltd. |
Taste masked aqueous liquid pharmaceutical composition
|
|
WO2003077847A2
(en)
|
2002-03-12 |
2003-09-25 |
Merck & Co., Inc. |
Substituted amides
|
|
WO2003082191A2
(en)
|
2002-03-28 |
2003-10-09 |
Merck & Co., Inc. |
Substituted 2,3-diphenyl pyridines
|
|
US7668730B2
(en)
|
2002-12-17 |
2010-02-23 |
JPI Commercial, LLC. |
Sensitive drug distribution system and method
|
|
WO2005004865A1
(en)
|
2003-07-08 |
2005-01-20 |
Georg-August-Universität Göttingen |
Use of 5-ht4(a)-serotonin receptor agonists
|
|
GB0410266D0
(en)
|
2004-05-07 |
2004-06-09 |
Ketocytonyx Inc |
Treatment of apoptosis
|
|
US9820658B2
(en)
|
2006-06-30 |
2017-11-21 |
Bao Q. Tran |
Systems and methods for providing interoperability among healthcare devices
|
|
CN101193588A
(zh)
|
2005-03-21 |
2008-06-04 |
海尔思-斯玛特有限公司 |
连续血压监测的系统
|
|
CN101257889A
(zh)
|
2005-05-25 |
2008-09-03 |
詹森药业有限公司 |
托吡酯的儿科制剂
|
|
CA2612180A1
(en)
|
2005-06-16 |
2006-12-21 |
Bionomics Limited |
Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
|
|
GB0515090D0
(en)
|
2005-07-22 |
2005-08-31 |
Birmingham Res & Dev Ltd |
Novel epilepsy treatment
|
|
EP1937255A4
(en)
|
2005-09-14 |
2013-06-26 |
Univ Witwatersrand Jhb |
PHARMACEUTICAL COMPOSITION
|
|
EP1958111A4
(en)
|
2005-11-29 |
2009-07-08 |
Childrens Hosp Medical Center |
OPTIMIZATION AND INDIVIDUALIZATION OF THE SELECTION AND DOSAGE OF MEDICAMENTS
|
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
RU2008135692A
(ru)
|
2006-02-06 |
2010-03-20 |
Новартис АГ (CH) |
Комбинация органический х-соединений
|
|
DE102006030113B4
(de)
|
2006-06-28 |
2009-02-12 |
Chemische Fabrik Budenheim Kg |
Graphitfreier Hochtemperatur-Schmierstoff
|
|
WO2008025148A1
(en)
|
2006-08-31 |
2008-03-06 |
The Governors Of The University Of Alberta |
Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
|
|
WO2008095095A2
(en)
|
2007-01-31 |
2008-08-07 |
Quintiles Transnational Corp. |
Methods and systems for allocating representatives to sites in clinical trials
|
|
JP2010520162A
(ja)
|
2007-02-28 |
2010-06-10 |
スミスクライン ビーチャム コーポレーション |
ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
|
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
|
CA3066426A1
(en)
|
2008-01-09 |
2009-07-16 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
|
US20110207718A1
(en)
|
2008-08-06 |
2011-08-25 |
Gosforth Centre (Holdings) Pty Ltd. |
Compositions and methods for treating psychiatric disorders
|
|
WO2010020585A1
(en)
|
2008-08-18 |
2010-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin reuptake inhibitors for the treatment of rett syndrome
|
|
SI2331210T1
(sl)
|
2008-09-05 |
2014-10-30 |
Gruenenthal Gmbh |
Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
|
|
US8386274B1
(en)
|
2008-09-17 |
2013-02-26 |
Mckesson Financial Holdings Limited |
Systems and methods for a prescription safety network utilizing eligibility verification transactions
|
|
MX2011003695A
(es)
*
|
2008-10-09 |
2011-08-17 |
A F S P A Aziende Chimiche Riunite Angelini Francesco A C R |
Formulacion farmaceutica liquida con contenido de paracetamol.
|
|
EP2355818A4
(en)
|
2008-10-10 |
2012-04-11 |
Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res |
METHOD AND COMPOSITIONS FOR TREATING THE STATUS EPILEPTICUS AND STATUS EPILEPTICUS CAUSING ATTACHMENTS
|
|
TWI424832B
(zh)
|
2008-12-15 |
2014-02-01 |
Proteus Digital Health Inc |
與身體有關的接收器及其方法
|
|
US20120065999A1
(en)
|
2009-03-09 |
2012-03-15 |
Celgene Corporation |
Device for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May Be Contraindicated and Methods for Use Thereof
|
|
AU2010236404B2
(en)
|
2009-04-15 |
2016-11-03 |
Research Triangle Institute |
Monoamine reuptake inhibitors
|
|
WO2010124137A1
(en)
|
2009-04-22 |
2010-10-28 |
Millennium Pharmacy Systems, Inc. |
Pharmacy management and administration with bedside real-time medical event data collection
|
|
US9453027B2
(en)
|
2009-07-27 |
2016-09-27 |
Daljit Singh Dhanoa |
Deuterium-enriched pyridinonecarboxamides and derivatives
|
|
UY33173A
(enExample)
|
2010-01-08 |
2011-07-29 |
Eurand Inc |
|
|
CA2792507C
(en)
|
2010-03-09 |
2018-05-22 |
Perceptimed, Inc. |
Medication verification and dispensing
|
|
WO2011119227A2
(en)
|
2010-03-25 |
2011-09-29 |
Columbia Northwest Pharmaceuticals, Llc |
Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
|
|
JP2011221623A
(ja)
|
2010-04-06 |
2011-11-04 |
Kakimori Suri |
在宅診療支援システム及び方法
|
|
AU2011255276B2
(en)
|
2010-05-21 |
2016-09-22 |
Research Triangle Institute |
Phenylmorpholines and analogues thereof
|
|
EP2399513B1
(en)
|
2010-06-23 |
2017-01-04 |
Qatar University Qstp-B |
System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
|
|
JP2013535469A
(ja)
|
2010-07-30 |
2013-09-12 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｃｙｐ３ａ薬物代謝の阻害
|
|
SG10201506874UA
(en)
|
2010-09-01 |
2015-10-29 |
Arena Pharm Inc |
Modified-release dosage forms of 5-ht2c agonists useful for weight management
|
|
US20120270848A1
(en)
|
2010-10-22 |
2012-10-25 |
Galleon Pharmaceuticals, Inc. |
Novel Compositions and Therapeutic Methods Using Same
|
|
US20140030343A1
(en)
|
2010-10-26 |
2014-01-30 |
Alpharma Pharmaceuticals Llc |
Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
|
|
RU103209U1
(ru)
|
2010-10-29 |
2011-03-27 |
Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" |
Клиническая информационная система
|
|
GB2487712B
(en)
|
2011-01-04 |
2015-10-28 |
Otsuka Pharma Co Ltd |
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
|
|
JP5693325B2
(ja)
|
2011-03-29 |
2015-04-01 |
小林クリエイト株式会社 |
健診結果出力システム及び健診結果出力プログラム
|
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
|
US20140348966A1
(en)
|
2011-12-22 |
2014-11-27 |
Onesmo B. Balemba |
Garcinia buchananii baker compounds, compositions and related methods
|
|
US9346798B2
(en)
|
2012-02-13 |
2016-05-24 |
Amgen Inc. |
Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
|
|
US20130218586A1
(en)
|
2012-02-21 |
2013-08-22 |
Frederic J. Huser |
Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
|
|
JP6075973B2
(ja)
|
2012-06-04 |
2017-02-08 |
富士通株式会社 |
健康状態判定装置およびその作動方法
|
|
BR112015011213A2
(pt)
|
2012-11-15 |
2017-08-29 |
Galleon Pharmaceuticals Inc |
Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
|
|
WO2014106825A2
(en)
|
2013-01-06 |
2014-07-10 |
Jonathan Rabinowitz |
Methods and devices for identifying improper medical reporting
|
|
US9549909B2
(en)
|
2013-05-03 |
2017-01-24 |
The Katholieke Universiteit Leuven |
Method for the treatment of dravet syndrome
|
|
PT3035926T
(pt)
|
2013-08-19 |
2020-09-01 |
Univ California |
Compostos e métodos para tratar um distúrbio epiléptico
|
|
WO2015066344A1
(en)
|
2013-11-01 |
2015-05-07 |
Arena Pharmaceuticals, Inc. |
5-ht2c receptor agonists and compositions and methods of use
|
|
US20150141415A1
(en)
|
2013-11-20 |
2015-05-21 |
Omonike Arike Olaleye |
Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
|
|
CN103886415A
(zh)
|
2014-03-25 |
2014-06-25 |
北京蝶禾谊安信息技术有限公司 |
药品管理方法和装置
|
|
GB2530001B
(en)
|
2014-06-17 |
2019-01-16 |
Gw Pharma Ltd |
Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
|
|
EP3201808B1
(en)
|
2014-09-29 |
2021-10-20 |
Zogenix International Limited |
Control system for control of distribution of medication
|
|
GB2531282A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
CA3254865A1
(en)
|
2015-02-06 |
2025-05-28 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
|
|
AU2016222804C1
(en)
|
2015-02-25 |
2021-10-14 |
The Regents Of The University Of California |
5HT agonists for treating disorders
|
|
US10292996B2
(en)
|
2015-03-26 |
2019-05-21 |
The Trustees Of Columbia University In The City Of New York |
Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
|
|
US10471087B2
(en)
|
2015-06-17 |
2019-11-12 |
The Trustees Of Columbia University In The City Of New York |
Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
|
|
JP6731427B2
(ja)
|
2015-06-30 |
2020-07-29 |
ネウラッド リミテッドＮｅｕｒａｄ Ｌｔｄ． |
新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
|
|
WO2017015309A1
(en)
|
2015-07-22 |
2017-01-26 |
John Hsu |
Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
|
|
MX389927B
(es)
|
2015-08-24 |
2025-03-20 |
Zogenix International Ltd |
Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
|
|
US20170071949A1
(en)
|
2015-09-14 |
2017-03-16 |
Zogenix International Limited |
Combination treatment of specific forms of epilepsy
|
|
EP3170807B1
(en)
|
2015-11-23 |
2019-12-11 |
Frau Pharma S.r.l. |
New method for synthesis of fenfluramine
|
|
CA3007286A1
(en)
|
2015-12-22 |
2017-06-29 |
Zogenix International Limited |
Fenfluramine compositions and methods of preparing the same
|
|
EP3393470B1
(en)
|
2015-12-22 |
2021-01-20 |
Zogenix International Limited |
Metabolism resistant fenfluramine analogs and methods of using the same
|
|
CN108699312B
(zh)
|
2016-01-14 |
2021-04-20 |
Ａｇｃ株式会社 |
含氟树脂溶液、含氟树脂溶液的制造方法、涂料组合物及涂装物品
|
|
MX2019001799A
(es)
|
2016-08-24 |
2019-06-13 |
Zogenix International Ltd |
Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
|
|
US20180092864A1
(en)
|
2016-09-30 |
2018-04-05 |
Zogenix International Limited |
Compositions and methods for treating seizure disorders
|
|
JP2020519594A
(ja)
|
2017-05-09 |
2020-07-02 |
ゾゲニクス インターナショナル リミテッド |
フェンフルラミンを用いるドゥーゼ症候群の治療方法
|
|
US20190091179A1
(en)
|
2017-09-26 |
2019-03-28 |
Zogenix International Limited |
Congnitive function with fenfluramine
|
|
WO2019067413A1
(en)
|
2017-09-26 |
2019-04-04 |
Zogenix International Limited |
USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
|
|
US10682317B2
(en)
|
2017-09-26 |
2020-06-16 |
Zogenix International Limited |
Ketogenic diet compatible fenfluramine formulation
|
|
MX2020010994A
(es)
|
2018-04-18 |
2021-01-08 |
Univ Columbia |
Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
|
|
WO2019216919A1
(en)
|
2018-05-11 |
2019-11-14 |
Zogenix International Limited |
Compositions and methods for treating seizure-induced sudden death
|
|
WO2019241005A1
(en)
|
2018-06-14 |
2019-12-19 |
Zogenix International Limited |
Compositions and methods for treating respiratory depression with fenfluramine
|
|
US20210113495A1
(en)
|
2018-07-10 |
2021-04-22 |
Zogenix International Limited |
Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertension
|
|
EA202191079A1
(ru)
|
2018-11-19 |
2021-09-20 |
Зодженикс Интернэшнл Лимитед |
Способы лечения синдрома ретта с применением фенфлурамина
|
|
US20210401776A1
(en)
|
2018-11-30 |
2021-12-30 |
Zogenix International Limited |
Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
|
|
JP2022521446A
(ja)
|
2019-02-25 |
2022-04-07 |
ゾゲニクス インターナショナル リミテッド |
発作制御を改善するための製剤
|
|
US20210299064A1
(en)
|
2020-02-05 |
2021-09-30 |
Zogenix International Limited |
Method of treating patients with lennox-gastaut syndrome
|
|
US11612574B2
(en)
|
2020-07-17 |
2023-03-28 |
Zogenix International Limited |
Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
|
|
US20220096514A1
(en)
|
2020-09-29 |
2022-03-31 |
Zogenix International Limited |
Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
|